[ {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE",
    "@type" : [ "http://www.nanopub.org/nschema#Nanopublication" ],
    "http://www.nanopub.org/nschema#hasAssertion" : [ {
      "@id" : "http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#assertion"
    } ],
    "http://www.nanopub.org/nschema#hasProvenance" : [ {
      "@id" : "http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#provenance"
    } ],
    "http://www.nanopub.org/nschema#hasPublicationInfo" : [ {
      "@id" : "http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#pubinfo"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#Head"
}, {
  "@graph" : [ {
    "@id" : "http://purl.obolibrary.org/obo/DOID_224",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Disease"
    } ]
  }, {
    "@id" : "http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#association",
    "@type" : [ "http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement" ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#object" : [ {
      "@id" : "http://purl.obolibrary.org/obo/DOID_224"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate" : [ {
      "@id" : "https://w3id.org/biolink/vocab/treats"
    } ],
    "http://www.w3.org/1999/02/22-rdf-syntax-ns#subject" : [ {
      "@id" : "https://identifiers.org/drugbank:DB06209"
    } ],
    "http://www.w3.org/2000/01/rdf-schema#label" : [ {
      "@value" : "\"* Active pathological bleeding ( 4.1 4.2 4.3 Prasugrel tablets are contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage  [see Warnings and Precautions ( 5.1 6.1 Prasugrel tablets is contraindicated in patients with a history of prior transient ischemic attack (TIA) or stroke. In TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel), patients with a history of TIA or ischemic stroke (>3 months prior to enrollment) had a higher rate of stroke on Prasugrel tablets (6.5%; of which 4.2% were thrombotic stroke and 2.3% were intracranial hemorrhage [ICH]) than on clopidogrel (1.2%; all thrombotic). In patients without such a history, the incidence of stroke was 0.9% (0.2% ICH) and 1.0% (0.3% ICH) with Prasugrel tablets and clopidogrel, respectively. Patients with a history of ischemic stroke within 3 months of screening and patients with a history of hemorrhagic stroke at any time were excluded from TRITON-TIMI 38. Patients who experience a stroke or TIA while on Prasugrel tablets generally should have therapy discontinued  [see Adverse Reactions ( 6.1 14 Prasugrel tablets is contraindicated in patients with hypersensitivity (e.g., anaphylaxis) to prasugrel or any component of the product  [see Adverse Reactions ( 6.2\""
    } ],
    "https://w3id.org/biolink/vocab/provided_by" : [ {
      "@id" : "https://w3id.org/um/NeuroDKG"
    } ],
    "https://w3id.org/biolink/vocab/relation" : [ {
      "@id" : "https://schema.org/MedicalContraindication"
    } ]
  }, {
    "@id" : "https://identifiers.org/drugbank:DB06209",
    "https://w3id.org/biolink/vocab/category" : [ {
      "@id" : "https://w3id.org/biolink/vocab/Drug"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#assertion"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#assertion",
    "http://www.w3.org/ns/prov#wasAttributedTo" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#provenance"
}, {
  "@graph" : [ {
    "@id" : "http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE",
    "http://purl.org/dc/terms/created" : [ {
      "@type" : "http://www.w3.org/2001/XMLSchema#dateTime",
      "@value" : "2021-08-23T18:39:25.828+02:00"
    } ],
    "http://purl.org/dc/terms/creator" : [ {
      "@id" : "https://orcid.org/0000-0002-1468-3557"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate" : [ {
      "@id" : "http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate" : [ {
      "@id" : "http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM"
    } ],
    "https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate" : [ {
      "@id" : "http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY"
    } ]
  }, {
    "@id" : "http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#sig",
    "http://purl.org/nanopub/x/hasAlgorithm" : [ {
      "@value" : "RSA"
    } ],
    "http://purl.org/nanopub/x/hasPublicKey" : [ {
      "@value" : "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"
    } ],
    "http://purl.org/nanopub/x/hasSignature" : [ {
      "@value" : "a7/H+AvkeDkIrMj9ymhEqSr5x182wkUxWk22OLLMrpAny1MY/RjC48HiSljXs5Qs8K8ioxbAQLMZU8St2Xf2s1c+/5ngtPrGymx5WDaxlQpIeuPLb7aKrNTYso/ePXP79LzpW3zvtcdI0r3u9wNH6ThPcyVIqpZHe3mBMeBQrO8="
    } ],
    "http://purl.org/nanopub/x/hasSignatureTarget" : [ {
      "@id" : "http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE"
    } ]
  } ],
  "@id" : "http://purl.org/np/RAzOMmCJBYu1Oo2-dM66bxsVH7gPP4DavFSPfPs-vQhbE#pubinfo"
} ]